EGFR C797S: What This Resistance Alteration Means
EGFR C797S is an acquired alteration that can emerge in some EGFR-mutant lung cancers after exposure to third-generation EGFR inhibitors. It is a molecular finding, not a treatment instruction: its meaning depends on the original EGFR driver, co-alterations, specimen and the exact report.
Quick Answer
EGFR C797S is an acquired alteration that can emerge in some EGFR-mutant lung cancers after exposure to third-generation EGFR inhibitors. It is a molecular finding, not a treatment instruction: its meaning depends on the original EGFR driver, co-alterations, specimen and the exact report.
Where C797S Fits
C797 sits in the EGFR kinase domain. Substitution at this position can alter the binding interaction used by some later-generation EGFR inhibitors, which is why it is studied as a resistance mechanism.
The report should be read alongside the baseline driver and other resistance findings. C797S is not synonymous with every form of progression, and it may be absent from a sample even when resistance is present elsewhere.
Why Testing Context Matters
A tissue specimen and a circulating-tumour-DNA sample have different strengths and limitations. A negative blood result can reflect low tumour DNA shedding rather than a definite absence of the alteration.
Whether C797S is reported with T790M and whether changes are on the same or different alleles are laboratory and interpretation questions. Preserve the full variant notation, assay and sample date for the oncology team.
Key Takeaways
- ·C797S is a resistance-associated EGFR finding, not a stand-alone diagnosis.
- ·Its interpretation depends on the original driver, co-alterations and testing method.
- ·A molecular report needs clinical review before it is used in a treatment decision.
Put these genes in pathway context
Frequently asked questions
What is the key idea in EGFR C797S: What This Resistance Alteration Means?
EGFR C797S is an acquired alteration that can emerge in some EGFR-mutant lung cancers after exposure to third-generation EGFR inhibitors. It is a molecular finding, not a treatment instruction: its meaning depends on the original EGFR driver, co-alterations, specimen and the exact report.
What should be kept with the result or mechanism?
C797S is a resistance-associated EGFR finding, not a stand-alone diagnosis. Its interpretation depends on the original driver, co-alterations and testing method. A molecular report needs clinical review before it is used in a treatment decision.
References
- 1EGFR C797S, an acquired resistance mutation to third-generation EGFR inhibitors. Journal of Thoracic Oncology, 2015. PubMed
- 2EGFR T790M mutation and resistance to EGFR inhibitors. New England Journal of Medicine, 2008. PubMed
- 3Molecular testing guideline for lung cancer. Journal of Thoracic Oncology, 2018. PubMed
Continue Reading
MAPK Pathway Resistance: A Framework for Reading Resistance Reports
2 min read
EGFR Exon 19 Deletions: What the Biomarker Means
4 min read
EGFR L858R: Understanding the Exon 21 Mutation
3 min read
EGFR T790M: A Gatekeeper Resistance Mutation
3 min read
MET Amplification in EGFR-Mutant Cancer: A Resistance Mechanism
2 min read
Liquid Biopsy vs Tissue Testing: What Each Sample Can Tell You
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
EGFR has 1000+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.